Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02486042 · ClinicalTrials.gov registry record · Phase 2
Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02486042 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 48 participants.
The verdict
NCT02486042, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Retinopathy of prematurity (ROP) is a blinding disease affecting infants born prematurely. These infants do not have enough essential fatty acids to structurally support the retina, the nerve tissue in the eye which allows us to see. A recent study showed that giving omega-3 (n-3) fatty acids to these infants soon after birth made them less likely to need invasive treatments for eye disease. This research trial will give young infants born prematurely n-3 fish oil treatment and look at how this changes factors in the blood that promote disease. Detailed blood studies comparing infants with and without ROP will be performed and the infants will be followed over time to assess their eye development.
Interventions
- DRUG Omegaven
- DIETARY_SUPPLEMENT Standard lipids (primarily omega-6 fatty acids)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02486042
The ClinicalTrials.gov registry entry for NCT02486042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Omegaven is the first listed.
NCT02486042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02486042 about?
NCT02486042 is a clinical study titled "Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity". Retinopathy of prematurity (ROP) is a blinding disease affecting infants born prematurely. These infants do not have enough essential fatty acids to structurally support the retina, the nerve tissue in the eye which allows us to see. A recent study showed that giving omega-3 (n-3) fatty acids to the...
What is the current status of trial NCT02486042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2014-03. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02486042?
The interventions under investigation include: Omegaven (DRUG), Standard lipids (primarily omega-6 fatty acids) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02486042?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.